Ann: Mount Peake Development Update, page-152

First 152 Last

Share
Profile

Follow
noodly

6,788 Posts.

403

15/03/18

06:22

Post #: 31763680
Share

Originally posted by maxter ↑

Bombeiro911, my view is the relatively new plays (AVL is not, it was "Yellow Rock Resources" and changed its name and profile to emulate the now non player "American Vanadium Corp" "AVC") but is included, are exciting the market as trades and also dont have the struggling history that is so easily associated to with TNG.

What peeps fail to understand is the road TNG has travelled may well be the road these plays must travel too. That is a time line from commencement of a metallurgical development process to proving it up for financial consideration (DFS) that has taken TNG over 5 years.

I hope for them the path is smoother and shorter but at this juncture there is no guarantees. They will need to prove recovery percentages, purity grades and then all in costs after extensive background work a DFS that well exceeds an IRR of better than 25% ( TNG is c 44%). That is without consideration of approvals and consents and Off Takes. To think that at this juncture that road is guaranteed is a pipe dream. That is not to say it wont happen but wow there is are a lot of hurdles to jump.

So TNG sits in the enviable position of being the likely markets next primary vanadium producer with a plethora of products and one, titanium, capable of trumping all other comodities. But the market appears weary and cautious. It will only take a couple of co/ making announcements to see the money and support to reverse and come in to TNG. But the market waits as do we. It will happen.

Expand

"are exciting the market as trades and also dont have the struggling history that is so easily associated to with TNG."

Totally agree Maxter plus we don't have the huge amount of shares in the hands of recent purchasers and traders. I mentioned in a previous post KRC has issued 290mil shares to Sophs and instos in the last 3-4 months.

TNG Price at posting: 15.0¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 38 more messages in this thread...

First 152 Last

Add TVN (ASX) to my watchlist

(20min delay)
Last 4.7¢		Change 0.001(2.17%)		Mkt cap ! $82.87M

Open	High	Low	Value	Volume
4.7¢	4.7¢	4.6¢	$22.37K	485.7K

Buyers (Bids)

No.	Vol.	Price($)
1	13507	4.6¢

Sellers (Offers)

Price($)	Vol.	No.
4.7¢	98465	3

View Market Depth

No.	Vol.	Price($)
1	13507	0.046
10	982198	0.045
1	227295	0.044
1	13000	0.043
1	1000000	0.042

Price($)	Vol.	No.
0.047	98465	3
0.048	60870	2
0.049	110000	2
0.050	6413708	7
0.053	147612	1

Last trade - 13.18pm 07/10/2024 (20 minute delay)

TVN (ASX) Chart

Ann: Mount Peake Development Update, page-152

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Mount Peake Development Update, page-152

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News